vorinostat has been researched along with Cancer of Esophagus in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Esophageal cancers are highly aggressive tumors with poor prognosis despite some recent advances in surgical and radiochemotherapy treatment options." | 1.42 | Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. ( Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M, 2015) |
| "This combined therapeutic effect on esophageal cancer epithelial-mesenchymal transition was associated with upregulation of E-cadherin protein expression." | 1.36 | Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. ( Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrens, TD | 1 |
| Timme, S | 1 |
| Hoeppner, J | 1 |
| Ostendorp, J | 1 |
| Hembach, S | 1 |
| Follo, M | 1 |
| Hopt, UT | 1 |
| Werner, M | 1 |
| Busch, H | 1 |
| Boerries, M | 1 |
| Lassmann, S | 1 |
| Nandakumar, V | 1 |
| Hansen, N | 1 |
| Glenn, HL | 1 |
| Han, JH | 1 |
| Helland, S | 1 |
| Hernandez, K | 1 |
| Senechal, P | 1 |
| Johnson, RH | 1 |
| Bussey, KJ | 1 |
| Meldrum, DR | 1 |
| Taylor, MD | 1 |
| Liu, Y | 1 |
| Nagji, AS | 1 |
| Theodosakis, N | 1 |
| Jones, DR | 1 |
3 other studies available for vorinostat and Cancer of Esophagus
| Article | Year |
|---|---|
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Topics: Acetylation; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; | 2015 |
Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells.
Topics: Cell Line, Tumor; Cell Nucleus; Cell Survival; Epithelial Cells; Esophageal Neoplasms; Esophagus; Hi | 2016 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezo | 2010 |